Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions
CPT: Pharmacometrics & Systems Pharmacology · 2026-03 · 15 (3)
DOI: 10.1002/psp4.70230 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 07.03.2026. Verfasst von Fei Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genentech Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Models, Biological, Pruritus, Antipruritics. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Vixarelimab is a first‐in‐class fully human monoclonal antibody targeting oncostatin M (OSM) receptor beta (OSMRβ). It has been evaluated in Phase 1 and 2 studies in healthy volunteers and patients with chronic pruritic conditions and demonstrated anti‐pruritic efficacy in a Phase 2 study in prurigo nodularis, but detailed pharmacokinetic analysis has not been previously reported. In this study, a population pharmacokinetic analysis was performed to characterize the pharmacokinetics of vixarelimab and identify covariates affecting exposure. The analysis dataset contained 4032 measurements from 274 participants from three Phase 1 and 2 studies. A two‐compartment target‐mediated drug disposition (TMDD) model with a quasi‐steady‐state (QSS) approximation satisfactorily described the observed concentration‐time data across studies and various dose levels. The model estimated linear clearance (CL), central volume ( V c ), and peripheral volume ( V p ) at 0.00649 L/h, 3.04 L, and 1.74 L, respectively, in line with values for a typical monoclonal antibody. Subcutaneous bioavailability and the absorption rate constant were estimated to be 56.6% and 0.0126 h −1 , respectively. Body weight was identified as the only statistically significant covariate, positively correlating with CL, V c , and V p . Model‐based simulations showed that the clinical impact of body weight on vixarelimab exposure was minor, suggesting that dose adjustment based on weight is not warranted. The developed model provides a thorough understanding of vixarelimab pharmacokinetics and the impact of covariates on exposure to support future clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genentech Inc., South San Francisco, California, USA.
ORCID-Profile: Fei Tang, Nastya Kassir
Zitieren
APA
Tang, F., Dang, S., Arjomandi, A., Pan, L., Hsu, J., Kshirsagar, S., & Kassir, N. (2026). Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions. CPT: Pharmacometrics & Systems Pharmacology, 15(3). https://doi.org/10.1002/psp4.70230
Vancouver
Tang F, Dang S, Arjomandi A, Pan L, Hsu J, Kshirsagar S, et al. Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(3). doi:10.1002/psp4.70230
BibTeX
@article{Tang2026,
author = {Tang, Fei and Dang, Steve and Arjomandi, Audrey and Pan, Lin and Hsu, Joy and Kshirsagar, Smita and Kassir, Nastya},
title = {Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/psp4.70230}
}
EUVIMED